ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY

被引：7
作者：
Cohen, S. [1 ]
Pablos, J. L. [2 ]
Wang, H. [3 ]
Mueller, G. A. [4 ]
Kivitz, A. [5 ]
Matsumoto, A. [6 ]
Krishnan, E. [3 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Inst Invest Hosp, Madrid, Spain
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Abt Nephrol & Rheumatol, Gottingen, Germany
[5] Altoona Ctr Clin Res, Duncansville, PA USA
[6] Arthrit & Rheumatism Associates, Wheaton, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.3288
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0171
引用
收藏
页码：834 / 835
页数：2
相关论文
共 50 条
  • [21] Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
    Hobbs, K.
    Wallace, D. J.
    Strand, V.
    Kalunian, K.
    Kilgallen, B.
    Bongardt, S.
    Wegener, W. A.
    Goldenberg, D. M.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S276 - S277
  • [22] Safety and efficacy of aceneuramic acid in GNE myopathy: open-label extension study
    Suzuki, Naoki
    Mori-Yoshimura, Madoka
    Katsuno, Masahisa
    Takahashi, Masanori P.
    Yamashita, Satoshi
    Oya, Yasushi
    Hashizume, Atsushi
    Yamada, Shinichiro
    Nakamori, Masayuki
    Izumi, Rumiko
    Kato, Masaaki
    Warita, Hitoshi
    Tateyama, Maki
    Kuroda, Hiroshi
    Asada, Ryuta
    Yamaguchi, Takuhiro
    Nishino, Ichizo
    Aoki, Masashi
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (11) : 1093 - 1094
  • [23] LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: FINAL RESULTS FROM THE PHASE 2 OPEN-LABEL EXTENSION STUDY
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip J.
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S1198 - S1198
  • [24] Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study
    Ferrante, M.
    Feagan, B. G.
    Panes, J.
    Baert, F.
    Louis, E.
    Dewit, O.
    Kaser, A.
    Duan, W. R.
    Gustafson, D.
    Liao, X.
    Wallace, K.
    Kalabic, J.
    D'Haens, G. R.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S024 - S025
  • [25] Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis
    Papp, Kim
    Leonardi, Craig
    Gordon, Kenneth
    Frevert, Lisa
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB193 - AB193
  • [26] Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study
    Strober, B.
    Poulin, Y.
    Kerdel, F.
    Langley, R.
    Menter, A.
    Papp, K.
    Gu, Y.
    Okun, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 9 - 9
  • [27] Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
    Strober, Bruce
    Okun, Martin
    Gu, Yihua
    Poulin, Yves
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB124 - AB124
  • [28] Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study
    Ogata, Atsushi
    Amano, Koichi
    Dobashi, Hiroaki
    Inoo, Masayuki
    Ishii, Tomonori
    Kasama, Tsuyoshi
    Kawai, Shinichi
    Kawakami, Atsushi
    Koike, Tatsuya
    Miyahara, Hisaaki
    Miyamoto, Toshiaki
    Munakata, Yasuhiko
    Murasawa, Akira
    Nishimoto, Norihiro
    Ogawa, Noriyoshi
    Ojima, Tomohiro
    Sano, Hajime
    Shi, Kenrin
    Shono, Eisuke
    Suematsu, Eiichi
    Takahashi, Hiroki
    Tanaka, Yoshiya
    Tsukamoto, Hiroshi
    Nomura, Akira
    [J]. JOURNAL OF RHEUMATOLOGY, 2015, 42 (05) : 799 - 809
  • [29] Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
    Goemans, Nathalie M.
    Tulinius, Mar
    van den Hauwe, Marleen
    Kroksmark, Anna-Karin
    Buyse, Gunnar
    Wilson, Rosamund J.
    van Deutekom, Judith C.
    de Kimpe, Sjef J.
    Lourbakos, Afrodite
    Campion, Giles
    [J]. PLOS ONE, 2016, 11 (09):
  • [30] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
12345